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Background: Although genome-wide association studies (GWAS) have identified hundreds of variants associated
with a risk for autoimmune and immune-related disorders (AID), our understanding of the disease mechanisms is
still limited. In particular, more than 90% of the risk variants lie in non-coding regions, and almost 10% of these
map to long non-coding RNA transcripts (lncRNAs). lncRNAs are known to show more cell-type specificity than
protein-coding genes.
Methods: We aimed to characterize lncRNAs and protein-coding genes located in loci associated with nine AIDs
which have been well-defined by Immunochip analysis and by transcriptome analysis across seven populations of
peripheral blood leukocytes (granulocytes, monocytes, natural killer (NK) cells, B cells, memory T cells, naive CD4+
and naive CD8+ T cells) and four populations of cord blood-derived T-helper cells (precursor, primary, and polarized
(Th1, Th2) T-helper cells).
Results: We show that lncRNAs mapping to loci shared between AID are significantly enriched in immune cell
types compared to lncRNAs from the whole genome (α <0.005). We were not able to prioritize single cell types
relevant for specific diseases, but we observed five different cell types enriched (α <0.005) in five AID (NK cells for
inflammatory bowel disease, juvenile idiopathic arthritis, primary biliary cirrhosis, and psoriasis; memory T and CD8+
T cells in juvenile idiopathic arthritis, primary biliary cirrhosis, psoriasis, and rheumatoid arthritis; Th0 and Th2 cells
for inflammatory bowel disease, juvenile idiopathic arthritis, primary biliary cirrhosis, psoriasis, and rheumatoid
arthritis). Furthermore, we show that co-expression analyses of lncRNAs and protein-coding genes can predict the
signaling pathways in which these AID-associated lncRNAs are involved.
Conclusions: The observed enrichment of lncRNA transcripts in AID loci implies lncRNAs play an important role in
AID etiology and suggests that lncRNA genes should be studied in more detail to interpret GWAS findings correctly.
The co-expression results strongly support a model in which the lncRNA and protein-coding genes function together
in the same pathways.* Correspondence: s.withoff@umcg.nl
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Autoimmune and immune-related disorders (AID) are a
heterogeneous group of disorders that occur in 7 to 9%
of people worldwide [1]. These diseases are caused by an
inappropriate response of the human immune system
against self-antigens. As we have gained more insight
into the biological mechanisms underlying different
AID, it has become clear that clinically distinct AID with
diverse phenotypic manifestations (systemic or organ-
specific) share features such as pathophysiological mech-
anisms, the involvement of human leukocyte antigen
(HLA) susceptibility alleles, the production of antibodies
to self-antigens, and genetic susceptibility [2-6].
Thus far, many different AID loci have been identi-
fied by genome-wide association studies (GWAS) and
these are listed in the GWAS catalog [7]. The 186 AID
loci known in 2010 resulted in the design of a dedi-
cated SNP array, Immunochip, to fine-map them [8].
By integrating GWAS and Immunochip data with Gen-
code data from the Encyclopedia of DNA Elements
(ENCODE) project, it has become clear that more than
90% of the AID-associated SNPs map to non-coding,
regulatory regions [9,10] that may encompass non-
coding RNA genes [11]. Using expression quantitative
trait loci (eQTLs) analysis, we recently demonstrated
that SNPs associated with complex diseases can affect
the expression of long non-coding RNAs (lncRNAs),
suggesting that lncRNA genes are disease-susceptibility
candidate genes [12].
lncRNAs are defined to be >200 nucleotides in size,
contain intron/exon structure, can be expressed as alter-
natively spliced variants, but lack coding potential. They
show, on average, expression at 2 logarithmic lower
levels than protein-coding genes and it has been sug-
gested that they can be expressed in a more cell type-
specific manner than protein-coding genes [11,13,14].
Although their mechanisms of action are diverse, and
not fully understood, their major function seems to be
the regulation of gene expression, thus adding yet an-
other layer of complexity to our understanding of how
gene expression is regulated [15].
Recent studies have clearly demonstrated that lncRNA
expression or function can be dysregulated in human dis-
eases [12,16,17] like cancer [18-21], neurological disorders
[22,23], HELLP syndrome [24], and microbial suscepti-
bility [25]. It has also been established that lncRNAs are
involved in the regulation of the immune system: in
NFκB signaling, in the anti-viral response, in CD4+ and
CD8+ T-cell differentiation, and in the inflammatory re-
sponse [26-30]. We have recently shown that approxi-
mately 10% of AID-associated SNPs localize to lncRNA
genes present in AID-associated loci [10], suggesting
that the lncRNAs they encode play a role in disease
etiology.Here, we provide evidence supporting the hypothesis
that lncRNA genes in AID loci may be important in
disease etiology. Analyses of RNA sequencing (RNA-
seq) data obtained from 11 distinct immune cell-type
subsets showed enriched expression of lncRNAs lo-
cated in AID loci in these cells, and allowed us to infer
disease-specific immune cell subsets. To obtain more
insight into the function of these lncRNAs, we performed
co-expression analysis of protein-coding and lncRNA
genes. This ‘guilt-by-association’ approach identified spe-




This study was approved by the Medical Ethical Board
of University Medical Center Groningen (one blood
sample was obtained from a healthy donor who signed
an institutional review board protocol), and by the Ethics
Committee of the Hospital District of Southwest Finland
(naive umbilical cord blood samples from healthy neo-
nates born in Turku University Central Hospital) in line
with the guidelines of the 1975 Declaration of Helsinki.
Informed consent was obtained in writing from each
subject.
Autoimmune disease locus definition
We selected all autoimmune and immune-related dis-
eases with published Immunochip data (as of 1 June
2013) and extracted all the non-HLA signals with inde-
pendent genome-wide associations (top SNPs; P ≤ 5 ×
10-8). Independent association signals in regions with
multiple associations were defined by applying stepwise
logistic regression conditioning on the most significant
variant. The Immunochip is a custom-made array con-
taining approximately 200,000 SNPs across 186 GWAS
loci for autoimmune and immune-mediated diseases. It
was designed for cost-effective dense sequencing, to
identify causal variants or more strongly associated vari-
ants in AID [8]. Disease-associated loci were defined as
regions harboring the top SNPs and their proxy SNPs
(r2 ≥ 0.5), which were extracted with the SNAP tool [31].
We used either the 1000 Genomes Pilot dataset [32] or the
HapMap 3 (release 2) dataset [33], with the CEU popula-
tion as a reference with a window of ±500 kb. For four top
SNPs (rs13397, rs2097282, rs34536443, rs59466457) that
were not present in both datasets, the specific disease-
associated loci were defined as a 1 Mb region around the
top SNP (top SNP ±500 kb; Figure S1 in Additional file 1)
in analogy to what has been used in cis-eQTL analysis of
significant associations [34]. We used the Intersect Bed
method from the BEDTools suite [35] to obtain the over-
lapping regions between different diseases and marked
them as AID shared loci.
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granulocytes
Venous peripheral blood (60 ml) from a healthy donor
was collected in a lithium-heparin BD Vacutainer tube
(BD, Franklin Lakes, NJ, USA). Peripheral blood mono-
nuclear cells (PBMCs) were isolated by Ficoll Paque Plus
(GE Healthcare Life Sciences, Uppsala, Sweden) gradient
centrifugation and subjected to staining for fluorescence-
activated cell sorting (FACS) analysis. The red blood cells
in the pellet were lysed with monochloride solution (155
mM NH4Cl, 10 mM KHCO3, 0.1 mM Na2.EDTA.2H2O,
pH 7.4) to yield the granulocyte fraction.
Flow sorting of immune cell subsets from the PBMC fraction
The PBMCs were incubated with antibodies for 45 minutes
at 4°C and sorted in six different populations on the
MoFlo™ XDP flow cytometer (Beckman Coulter, Brea, CA,
USA). First, lymphocytes and monocytes were separated
based on forward and side scatter profiles. For further
separation of lymphocytes, gates were created for CD4-
CD8- CD56/CD16+ CD19- (natural killer (NK) cells), CD4-
CD8- CD56/CD16- CD19+ (B cells), CD4+ CD8- CD45RO-
(naive CD4+), CD4- CD8+ CD45RO- (naive CD8+), CD4+
CD8- CD45RO+ and CD4- CD8+ CD45RO+ (memory T
cells) cells. Anti-CD8a-APC-eF780 and anti-CD4-eF450
were obtained from eBioscience (San Diego, CA, USA),
anti-CD45RO-FITC and anti-CD19-AF700 from BD Bio-
sciences, and anti-CD56-Pe and anti-CD16-Pe from IQ-
Products (Groningen, the Netherlands).
RNA isolation and preparation of RNA sequencing libraries
RNA was extracted from all seven immune cell types
(granulocytes, monocytes, NK cells, B cells, memory T
cells (both CD4+ and CD8+), naive CD4+ (T-helper cells)
and naive CD8+ (cytotoxic T cells) using the MirVana
RNA isolation kit (Ambion, Life Technologies, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
We determined RNA quantity and quality using the
Nanodrop 1000 Spectrophotometer (Thermo Scientific,
Waltham, MA, USA) and the Experion high-sensitivity
RNA analysis kit (Bio-Rad, Hercules, CA, USA), respect-
ively. The RNA was concentrated by precipitation and re-
diluted in a smaller volume. The sequencing libraries were
prepared from 1 μg of total RNA using the TruSeq RNA
kit (Illumina, San Diego, CA, USA) according to the man-
ufacturer’s instructions. Each RNA library was sequenced
in a single lane on the Illumina HiSeq2000 (Illumina).
RNA sequencing of polarized human T-cell subsets
derived from cord blood
Human naive umbilical cord blood CD4+ T-helper cells
were isolated from healthy neonates born in Turku
University Central Hospital and polarized into different
T-helper cell subsets (precursor T-helper cells (ThP),primary T-helper cells (Th0) and polarized T cells (Th1,
Th2)) as previously described [36]. Briefly, purified naive
CD4+ T cells were activated with plate-bound anti-CD3
antibody (2.5 mg/ml for coating) and 500 ng/ml soluble
anti-CD28 antibody (Immunotech, Marseille, France).
Th1 cell polarization was initiated with 2.5 ng/ml IL-12
(R&D Systems, Minneapolis, MN, USA) and Th2 cell
neutralizing antibody anti-IL-4 (1 μg/ml). To promote
Th2 cell differentiation, 10 ng/ml IL-4 (R&D Systems)
and Th1 cell neutralizing antibody anti-interferon gamma
(1 μg/ml) was used. To obtain the Th0 population, only
the neutralizing antibodies were added. At 48 hours, 40
U/ml IL-2 (R&D Systems) was added to the cultures [36].
After 7 days the polarized cells were collected and RNA
was isolated using Trizol (Invitrogen, Life Technologies).
The sequencing libraries were prepared from 400 ng of
total RNA using the TruSeq RNA kit (Illumina) according
to the manufacturer’s instructions and were sequenced on
the Illumina HiSeq2000 (Illumina).
Analysis of RNA sequencing data
The quality of the raw reads was confirmed using
FastQC [37] and reads were mapped to the human refer-
ence genome (NCBI build 37) using STAR version 2.1.3
[38], allowing for two mismatches and retaining only
uniquely mapping reads. The aligner was provided with
a file containing junctions from Ensembl GRCh37.65.
Reads that corresponded to flag 1796 in the bam align-
ment file (flag 1796: read unmapped, not primary align-
ment, read fail quality check, read is PCR or optical
duplicate) were filtered out. To estimate expression levels
in RNA deep sequencing data, the number of reads that
overlapped with exons from known transcripts (as de-
scribed in Gencode version 14 [14]) by no less than 30% of
the read’s length were quantified using the IntersectBed tool
from the BEDTools suite [35]. Subsequently, the reads were
normalized, and normalized expression RPKM (reads per
kilobase per million mapped reads) values were calculated
using the formula RPKMg = 10
9 × (Cg/(N × Lg)) [39], where
Cg is the number of reads that map into the exons of gene
g; Lg is the length of the exons of gene g; and N is the total
number of mapped reads for this sample. RPKM values for
all Gencode version 14 genes were computed at the gene
levels obtained for all 11 immune cell types, respectively.
Gencode version 14 data [14] were used to annotate these
regions with protein-coding and lncRNA genes using the
IntersectBed tool from BEDTools suite [35]. Circular dia-
grams showing the genes shared between the various auto-
immune diseases were produced using Circos [40].
Differences in expression between AID- or disease-
specific loci and the whole Gencode reference were tested
using the two-tailed Fisher’s exact test, and the P-values
were corrected for multiple testing with the Bonferroni
correction. The statistically significant thresholds for
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cell types were P ≤ 0.007 (level of significance (α) = 0.05),
P ≤ 0.001 (α = 0.01), and P ≤ 0.0007 (α = 0.005), and in
four cord blood CD4+ T-cell lineages they were P ≤ 0.012,
P ≤ 0.002, and P ≤ 0.0012, respectively.
The normalized gene expression values (RPKM) were
log10 transformed. For zero expression (0 RPKM) a
0.000001 value was added to the RPKM value and log10
transformed. Heat maps of the transformed RPKM data
were created in Gene-E and unsupervised hierarchical
clustering of the samples was performed using the ‘aver-
age linkage’ clustering method with the Euclidean dis-
tance metric [41].
The RNA sequencing data from this study are avail-
able from Gene Expression Omnibus [42], accession
number GSE62408.
Results
Selection of AID phenotypes
In order to investigate the shared genetics of autoimmune
and immune-related diseases, we selected eight different
AID for which dense-mapped Immunochip data were
available (per 1 June 2013): autoimmune thyroid disease
[43], celiac disease (CeD) [44], inflammatory bowel disease
(IBD) [45], juvenile idiopathic arthritis (JIA) [46], primary
biliary cirrhosis (PBC) [47], psoriasis (PS) [48], primary
sclerosing cholangitis (PsCh) [49] and rheumatoid arthritis
















CD 29 29 338 123,953 -
CeD 32 30 246 125,799 -
IBD (shared) 97 95 984 139,174 2
JIA 16 15 112 152,964 -
PBC 18 16 143 176,717 1
PS 33a 32 287 111,617 -
PsCh 12 12 81 227,273 -
RA 26 23 132 96,343 -
UC 22 22 198 127,674 -
Total 285 274 2,521 142,390 3
CD, Crohn’s disease-specific; CeD, celiac disease; IBD (shared), inflammatory bowel d
arthritis; PBC, primary biliary cirrhosis; PS, psoriasis; PsCh, primary sclerosing cholan
characterized by the number of genome-wide significant SNPs associated with the
them. We subdivided inflammatory bowel disease loci into Crohn’s disease-specific
to reveal phenotype-specific features. aPsoriasis (PS) was associated with 33 genom
one locus (chr.19: 10,745,764-10,894,728) is located within a bigger 1 Mb locus (chr
of AID loci 284. In summary, the total number of AID-associated SNPs was 285 and
the reference dataset (Gencode version 14), we discovered 950 protein-coding gen
phenotypes (AID-shared coding genes) and 626 were unique across all diseases (AI
shared (AID-shared lncRNAs) and 240 unique genes (AID-lncRNAs).(CD)-specific loci, ulcerative colitis (UC)-specific loci, and
CD-UC shared loci (IBD shared) to reveal phenotype-
specific features. Autoimmune thyroid disease was ex-
cluded from further analysis since only two SNPs reported
in this study [43] passed the stringent genome-wide
P-value cutoff (P ≤ 5 × 10-8). We thus had nine disease
phenotypes to analyze: CD, CeD, IBD shared, JIA, PBC,
PS, PsCh, RA, and UC.
Locus definition and overlap between other AIDs
After selecting the disease phenotypes, we defined the loci
associated with the individual phenotypes (Additional
file 1), resulting in a total number of 284 loci (Table 1;
Additional file 2). Of these 284 loci, 119 loci overlapped
partly or completely in two or more AID and are referred
to as ‘AID shared loci’ (Additional file 3). Next, we exam-
ined whether the size of the shared loci was related to the
number of diseases it was associated with, but we ob-
served no enrichment of the number of AIDs in any spe-
cific size class (Figure S2A,B in Additional file 4).
Annotation of protein-coding and non-coding genes in
AID loci
To identify lncRNAs and protein-coding genes localized
in selected loci, we annotated all 284 AID loci with
Gencode V14 data. This resulted in 240 lncRNAs and
626 protein-coding genes in these loci as shown in
Table 1. More detailed information about the specificluded in this study










- - - 50 14 [45]
- 2 1,000,000 127 37 [44]
172,626 2 1,000,000 254 107 [45]
- 1 1,000,000 73 20 [46]
859,903 2 1,000,000 90 38 [47]
- 1 1,000,000 131 48 [48]
- - - 50 17 [49]
- 3 1,000,000 127 36 [50]
- - - 48 24 [45]
516,265 11 1,000,000 950 341
isease shared by Crohn’s disease and ulcerative colitis; JIA, juvenile idiopathic
gitis; RA, rheumatoid arthritis; UC, ulcerative colitis-specific. Each disease is
disease phenotype, the number of disease loci, and the genes located inside
loci (CD), ulcerative colitis-specific loci (UC), and CD-UC shared loci (IBD shared)
e-wide significant SNPs. After defining the PS disease loci, we discovered that
.19: 9,963,118-10,963,118), resulting in 32 PS loci and making the total number
these led to 284 AID loci. After all the disease loci annotation with genes from
es in total but 186 of them were shared between at least two disease
D-coding genes). For lncRNAs, the total number of genes was 341, with 61
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ease phenotype (Additional file 5) and by chromosome
coordinates (Additional file 6). We observed a lncRNA
to protein-coding gene ratio of approximately 1:3 in all
but one disease (UC-specific loci were represented by a
1:2 ratio), which is nearly double the 1:1.6 genome-
wide ratio calculated from using all 12,933 lncRNAs
and 20,074 protein-coding genes (Table 1).
Since we observed frequent overlap at the disease
locus level, we then investigated the inter-disease overlap
at the gene level as well (Figure 1). As expected, the pro-
file for the number of shared protein-coding genes was
almost identical to that found for the shared lncRNAs,
suggesting that lncRNAs might be similar in their level
of importance to that of protein-coding genes in AIDs
(Additional files 7, 8, 9, 10, 11, 12, and 13). For example,
the highest number of shared lncRNAs (11), as well as
the highest number of protein-coding genes (51), was
observed between RA and CeD (representing 31% of all
RA lncRNAs and 30% of all CeD lncRNAs versus 40% of
all RA protein-coding genes and 40% of all CeD protein-
coding genes) (Additional files 7, 8, and 9), which agrees
with previous findings from the literature [51].
Expression pattern of lncRNA and protein-coding genes
in distinct immune cell subsets
Immune cells are the major ‘disease effector’ cell types
in AIDs and previous studies have reported a criticalFigure 1 Circular diagrams showing the genes shared between nine a
circle in colored bands, with their abbreviated names. The ribbons depictin
phenotypes they are shared by (grey, two AIDs; blue, three AIDs; red, four
shown in this figure include genes specific to Crohn’s disease (CD), celiac d
and ulcerative colitis (IBD shared), juvenile idiopathic arthritis (JIA), primary bili
rheumatoid arthritis (RA), and ulcerative colitis specific (UC) genes. These tworole for T-cell differentiation and enrichment of causal
genes for Th1 and Th2 pathways [52-55]. Since data on
lncRNA genes are lacking, we investigated the expres-
sion levels of AID locus-encoded genes in seven circulat-
ing immune cell subsets and in four cell types during
CD4+ T-cell differentiation using the RNA-sequencing
data.
On average, the total number of sequencing reads per
sample was 137,411,294 for the seven immune cell subsets
and 199,151,275 reads for the polarized human T-cell sub-
sets generated from cord blood. Approximately 88% of the
reads were mapped to the reference genome on average.
Analyzing the expression data genome-wide, we see
for lncRNAs that, on average, 15% of all genes (1,881
out of 12,933) are expressed in the 11 cell types we in-
vestigated (Figure 2A). If we focus only on the expressed
lncRNAs from the AID loci and compare them to the
expressed lncRNAs from the whole genome (15%), we
see a two-fold increase to 32%, on average, representing
73 out of all 240 AID lncRNA genes. As can be seen
from Figure 2A, the range of gene expression in seven
circulating immune cell types is lower (23 to 33%) com-
pared with four types of differentiated CD4+ T cells (35
to 37%). Consistent with this observation, in both datasets,
we see similar enrichments of expression of protein-
coding genes encompassed within the AID loci (61%, 380
genes) compared with all Gencode protein-coding genes
(47%, 9,526 genes) (Figure 2B). All the reported differencesutoimmune diseases. The nine diseases are shown on the outer
g the shared genes are colored according to the number of disease
AIDs; black, five AIDs). (A) lncRNA genes and (B) protein-coding genes
isease (CeD), inflammatory bowel disease, shared by Crohn’s disease
ary cirrhosis (PBC), psoriasis (PS), primary sclerosing cholangitis (PsCh),
plots are presented at higher resolution in Additional files 8 and 9).
Figure 2 Proportion of genes expressed in different immune cells. (A) The number of lncRNA genes expressed (>2 RPKM) as a percentage
of all lncRNA genes genome-wide (n = 12,933) or as a percentage of all lncRNAs located in autoimmune disease loci (n = 240 genes). (B) The data for
the protein-coding genes genome-wide (n = 20,074) and the ones in AID loci (n = 626). Statistically significant enrichments (P-values) after Bonferroni
correction for multiple testing are denoted by asterisks to show the different levels of significance (*α < 0.05; **α < 0.01; ***α < 0.005).
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Bonferroni correction for multiple testing as shown in
Figure 2 and Additional file 14.
To determine which immune cell types are involved in a
specific disease, we then investigated associations between
lncRNA expression profiles and disease-specific loci for
each individual disease (Additional files 15 and 16).
Firstly, for four diseases, we observed enrichment of dif-
ferentially expressed lncRNAs between those in the dis-
ease loci and all Gencode lncRNAs (α < 0.005) in three
circulating immune cell types (NK cells for IBD, JIA,
PBC, PS; memory and CD8+ T cells for JIA, PBC, PS, RA;
Figure S6A in Additional file 11). Secondly, for five dis-
eases (IBD shared, JIA, PBC, PS (α < 0.01); RA (α < 0.05))
enrichment was observed for all four CD4+ T-cell subsets
tested (Figure S6B in Additional file 11). Thirdly, the
lncRNAs in the PS loci were differentially expressed in all
11 cell types (α < 0.005) (Figure S7F in Additional file 12;
Figure S8F in Additional file 13), suggesting that these
abundant lncRNAs in the PS loci may act in a less cell
type-specific manner but a more disease-specific one. As
shown in Additional file 11, we observed an interesting
but expected pattern of enrichment, in which protein-
coding genes in AID loci were significantly more expressed
in all the tested cell types than the protein-coding
genes from the whole Gencode dataset (Figure S6C,D
in Additional file 11). Similar enrichment was also seen
for lncRNAs, although the enrichment was more cell
type-specific (Figure S6A in Additional file 11), sup-
porting the characteristic attribute of lncRNAs as cell
type-specific transcripts.Gene expression distribution and levels in immune
cell subsets
To gain a detailed picture of lncRNA and protein-coding
gene expression profiles in our data, we computed the
gene expression distribution separately for both datasets
(Figure 3). Our data confirm that all Gencode lncRNA
are, in general, significantly less expressed than all
protein-coding genes (approximately five-fold lower in
both circulating (P = 0.00058) or T-helper cell subsets
(P = 0.029) (Figures 3A,B). Next, we focused our attention
on the gene expression distribution in AID loci and the
differences compared with the whole genome. We com-
puted the expression distribution of genes in AID loci and
compared it with the expression distribution of all
Gencode lncRNA and coding genes. Figure 3 shows that
lncRNAs associated with AID loci display an approxi-
mately 2.5-fold higher mean expression distribution than
all lncRNAs. In contrast, the protein-coding genes in the
AID loci displayed similar expression distributions com-
pared with all the coding genes in the Gencode dataset
(Figure 3).
Comparing the mean expression levels of lncRNAs
versus protein-coding genes in AID loci revealed only an
approximately two-fold lower expression of AID lncRNAs
(lncRNAs: in circulating peripheral cells = 6.80 RPKM; in
cord blood T-helper cells = 12.97 RPKM; coding genes: in
circulating cells = 14.01 RPKM; T-helper cells = 28.98
RPKM). This suggests that lncRNAs in disease-associated
loci are expressed to higher levels than previously assumed
and that they do so in cell types functionally involved in
the disease (Figure 3). Together, these findings suggest an
Figure 3 Mean expression distribution of lncRNAs and protein-coding genes. (A) Comparison of lncRNA expression genome-wide (LncRNA
Gencode, n = 12,933) with expression of lncRNAs located in AID loci (LncRNA AID, n = 240) and the expression of protein-coding genes genome-
wide (Protein Gencode, n = 20,074) with the expression of protein-coding genes located in AID loci (Protein AID, n = 626) in seven populations of
peripheral blood leukocytes. (B) Similar data for the T-helper cell populations derived from cord blood. Differences in the means of expression levels
between the two groups (disease loci (AIDs) versus genome-wide (Gencode)) were tested for significance using the Wilcoxon rank-sum test.
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in AID loci in immune cell biology and AIDs.
Analysis of lncRNA expression profiles
To examine the cell type-specific expression patterns of
individual lncRNAs, we created heat maps of all 240 AID
lncRNAs (Additional file 6) in the 11 cell types investi-
gated (Figure S7A in Additional file 15) and observed
small cell type-specific clusters of lncRNAs. For instance,
seven lncRNAs (RP11-324I22.2 (IBD), RP5-1011O1.2
(CeD), AC074391.1 (IBD), AC012370.2 (IBD), ALG9-IT1
(PsCh), BSN-AS1 (IBD, PsCh), CTC-349C3.1 (UC)) were
only expressed in four T-helper cell subtypes (ThP, Th0,
Th1 and Th2), whereas one lncRNA (CTD-2113 L7.1
(PBC)) was expressed in all the T cells investigated. Two
lncRNAs (AP002954.3 (CeD) and RP11-84D1.2 (PS)) were
detected in CD4+ T cells, CD8+ T cells, ThP, Th0, Th1 and
Th2 cells, but not in memory T cells.
Discussion
Interpreting the mechanisms of action of disease-
associated SNPs identified by GWAS is a challenge
because the vast majority of them are located in non-
coding regions that might play a more regulatory role.
An extra complication is the recent discovery of a new
class of regulatory RNAs, the lncRNAs. It has now been
recognized that many regions previously designated as
‘gene deserts’ actually harbor lncRNA genes. In this
study, we set out to investigate the nature of lncRNAs
present in AID loci in more detail, by analyzing gene
expression across 11 distinct immune cell types. We
assumed that lncRNAs that are highly expressed inparticular cell types are functionally active [11] and that
they can be used to prioritize disease-specific cell types.
We observed an expression enrichment of AID locus
genes (both protein-coding and lncRNAs) and con-
firmed the cell type-specific pattern of lncRNAs for AID
loci. For example, there are almost no publications on
the involvement of specific immune cells in UC versus
CD, while our data suggest that NK cells and granulocytes
are involved in both UC and CD (that is, in IBD-shared
loci), whereas T and B cells are associated specifically with
UC. In the case of RA, AID lncRNAs were more abundant
in the T-cell compartment (memory T, naive CD8+ T, ThP,
Th0, Th2 cells), which agrees with a study based on a stat-
istical approach to murine immune cells demonstrating
enrichment of protein-coding genes in CD4+ memory
T cells [56]. We observed no expression enrichment of
CeD genes in any of the cell types tested, suggesting
that the main effector cell type involved in the pathophysi-
ology of CeD might not have been represented by the cell
types present in our panel of cells. Gluten-reactive CD4+
T-cell clones or the autoreactive CD8+ T cells (intraepithe-
lial cytotoxic T lymphocytes) that have infiltrated into the
epithelium in the small intestine of CeD patients are
thought to be the key effector cells and these cells should
be included in future studies [5].
Many of the protein-coding genes in the AID loci are
known to play important roles in immune cell develop-
ment and/or function, but relatively little is known about
the role of lncRNAs in the immune system [25,28-30].
Co-expression analysis of transcripts is a promising strat-
egy to predict the function of lncRNA genes using a ‘guilt-
by-association’ approach. To date, most co-expression
Figure 4 RNA sequencing analysis of gene expression in seven peripheral blood leukocyte populations and four T-helper cell
populations from cord blood. The heat maps show the expression of all genes located in AID loci: (A) lncRNAs; (B) protein-coding genes and
AID genes shared by at least two diseases: (C) lncRNAs; (D) protein-coding genes. Unsupervised hierarchical clustering analysis of gene expression
profiles of all 11 cell types (granulocytes, monocytes, NK cells, B cells, memory T cells (both CD4+ and CD8+), naive CD4+and naive CD8+ T cells
(cytotoxic T cells), precursor T-helper cells (ThP), primary T-helper cells (Th0), and polarized T cells (Th1, Th2)). Heat maps represent log10 intensity
values. In the color scheme, saturated red indicates three-fold up-regulation, saturated green indicates three-fold down-regulation, and black
indicates unchanged expression.
Figure 5 An example of analyzing an autoimmune disease locus by pathway analysis approaches. (A) Expression levels of protein-coding
transcripts (FAM213B, MMEL1) and lncRNA genes (RP3-395 M20.8, RP3-395 M20.7, RP3-395 M20.9, RP13-436 F16.1) located in the MMEL1 locus
associated with four AIDs. The arrows pinpoint the data for RP3-395 M20.9. (B) Genes co-expressed with RP3-395 M20.9 are grouped in five
differently colored segments corresponding to the pathways predicted by GeneNetwork. (C) The top 10 Gene Ontology (GO) biological processes
predicted to be associated with the genes co-expressed with RP3-395 M20.9 are shown. (D) This schema shows a hypothetical mechanism of
action of RP3-395 M20.9. The disease-associated SNP is located between protein-coding gene A (tumor necrosis factor receptor superfamily,
member 14 (TNFRSF14, HVEM)) and lncRNA 1 (RP3-395 M20.9). This SNP only affects RP3-395 M20.9 directly. Two protein-coding genes (tumor
necrosis factor beta/lymphotoxin alpha (TNFb/LTA) on chromosome 6, and UBASH3A on chromosome 21) and one lncRNA (LINC00158 on
chromosome 21) are co-expressed with RP3-395 M20.9, which could be due to trans-regulation of these genes by RP3-395 M20.9. A hypothetical
cis-effect of lncRNA 1 (RP3-395 M20.9) on protein-coding gene TNFRSF14/HVEM in the same locus on chromosome 1 is also mentioned.
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that contain only a small subset of probes to lncRNAs
[12]. Despite this limitation, we used GeneNetwork [57],
which uses co-expression data to predict pathways and tis-
sues in which the query lncRNA could be involved. From
our 240 AID lncRNAs (Additional file 6; Figure S4A in
Additional file 8; a higher resolution figure is provided in
Figure S9A in Additional file 17), we selected those that
were associated with at least two AIDs (Figure 4C;
Additional file 12; Figure S9C in Additional file 17). Of
these 61 AID-lncRNAs, 9 were present in GeneNetwork,
which we then used to obtain Gene Ontology (GO) terms
associated with specific co-expression profiles (Additional
file 18) [58]. Based on these results, we could show, for in-
stance, that lncRNA RP3-395 M20.9 is co-expressed with
genes known to be involved in T- and B-cell biology
(Figure 5B). It is located in a locus shared by CeD, PsCh,
RA, and UC, and is abundant in monocytes and B and T
lymphocytes (B cells, memory T cells, CD4+ T cells, and in
all four cord blood T-helper cells) (Figure 5A). Seven of
the top 10 GO biological processes predicted to be associ-
ated with genes co-expressed with this lncRNA contained
‘tumor necrosis factor (TNF) pathway’ or ‘T-cell/lympho-
cyte event’ in their description (Figure 5C; Additional
file 18), confirming our results from expression ana-
lysis. Figure 5D visualizes the connection between the
lncRNA RP3-395 M20.9 and the co-expressed protein-
coding and non-coding genes proposed by GeneNet-
work. Now that the pathways and disease-relevant cell
types in which this lncRNA is involved are known, it
is easier to design appropriate functional follow-up
studies.
Here we show, for the first time, that AID lncRNA ex-
pression profiles predict cell type specificity better than
AID protein-coding genes. Our findings have implications
for identifying relevant disease-specific cell types, not only
for AIDs but also for other complex disorders. We realize
that by defining the disease loci, we may have excluded a
few causal genes, since they can be located outside these
loci due to more complex gene regulation. To address this
possibility, the next logical step would be to perform
eQTL analysis across a wide region and to analyze both
protein-coding and lncRNA genes. Preliminary results
from such an eQTL analysis of RNA sequencing data
generated from 673 whole blood samples suggest that the
majority of AID lncRNA eQTLs are cis-eQTLs (I Ricaño-
Ponce et al., personal communication). Ideally, the pro-
posed eQTL analyses should be performed using RNA
sequencing data obtained from individual immune cell
subsets rather than from whole blood, as is currently often
the case. As such datasets are likely to become available in
the near future, they will allow better co-expression-based
pathway analyses and, subsequently, a more precise pre-
diction of lncRNA function.In order to test our hypothesis of the involvement of
lncRNAs in immune cell signaling, laboratory-based ex-
periments need to be performed to validate the in silico
predictions and to elucidate the mechanism by which
the lncRNAs regulate the expression of protein-coding
genes. We were able to find lncRNA-protein-coding
gene pairs present in a single AID locus and these pairs
are co-regulated in specific immune cell types. For ex-
ample, the IL21-IL21-AS1 locus, associated with CeD,
JIA, PsCh, and IBD, contains four protein-coding genes
(KIAA1109, ADAD1, IL2, IL21) and one lncRNA (IL21-
AS1). IL21-AS1 exhibits a clear co-expression profile
with IL-21 in Th1 cells, where the level of IL21-AS1 is
similar to IL-21 (Additional file 19). We realize that enrich-
ment statistics or gene co-expression are not conclusive
with regard to causality and that functional studies
knocking-down protein-coding and/or lncRNA genes,
followed by rescuing experiments, are necessary.
Conclusions
Our results suggest that immune cell-specific expression
or function of lncRNAs is important in the etiology of
auto-immune diseases, possibly by regulating the expres-
sion of proteins critical for proper immune function.
Additional files
Additional file 1: Figure S1. A schematic illustration of our procedure
to define autoimmune disease loci. The independent association signals
in regions with multiple associations were defined using stepwise logistic
regression conditioning on the most significant variant. Disease-associated loci
were defined as regions containing the top SNP and its proxy SNPs (r2 ≥ 0.5)
selected either from the 1000 Genomes Pilot (1000G) dataset or from the
HapMap 3 dataset [32,33]. The disease locus was defined as a region with a
fixed size of 1 Mb (top SNP ±500 kb) when the top SNP was absent from
1000G and HapMap3. We defined a disease locus as having a fixed 1 Mb size
only in those cases that the disease-associated SNP was absent from the 1000
Genomes pilot and the HapMap 3 datasets. This was the case for only four
AID loci: one shared by five AIDs (JIA, PBC, PS, RA, IBD-shared), one shared by
RA and IBD; one shared by CeD and RA; and one CeD-only locus.
Additional file 2: Table S1. List of loci associated with nine autoimmune
diseases. For each disease phenotype, the table shows a list of loci including
additional information like chromosome position (Chr), genome coordinates
of the beginning in human genome build 19 (Start position (hg19)) and of
the end (End position (hg19)) of each locus, the size of the locus in base
pairs (Locus size [bp]) and the label of the disease loci (AID loci ID).
Additional file 3: Table S2 Visualization of AID loci shared between
autoimmune diseases. In this table we defined AID shared loci as those
with two or more diseases overlapping with the locus. Each AID shared
locus includes information about the number of AIDs overlapping this
region, the locus size in base pairs (Size [bp]) and the list of AID loci IDs.
Data are sorted based on the highest number of AIDs in one locus.
Additional file 4: Figure S2. Absence of a relationship between locus
size and the number of autoimmune diseases (AIDs) associated with
those loci. (A) Number of diseases sharing one AID locus (x-axis) versus
locus size distribution (y-axis). All the AID loci were grouped in five
differently colored segments based on the size range of each locus (<10
kb; 10 to 250 kb; 250 to 500 kb; 500 kb to 1 Mb; 1 Mb). (B) The
characteristics and distribution of AID loci. The number of AIDs
associated with a given locus is plotted on the x-axis. The green bars
represent the average locus size in base pairs (kb) on the left-hand y-axis.
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shared by a certain number of AIDs on the right-hand y-axis.
Additional file 5: Table S3. AID loci annotated with genes and listed
by disease phenotype. Each AID loci is annotated by protein-coding and
lncRNA genes either from Gencode version 14 reference (GencodeV14-
protein_coding (violet), GencodeV14 all_LncRNAs (green)) or from the
Human long intergenic non-coding RNAs (lincRNAs) catalog (Cabili_
LincRNAs (orange)). Each gene is characterized by its chromosome
number (Chr), the genome coordinates of the beginning in human
genome build 19 (START (hg19)) and end (END (hg19)), the gene name
(Gene ID (ENCODE/Cabili)), the identification number used in the
Ensembl database (Gene ID (Ensembl)), the strand specification (Strand)
and color coded information about the gene type (Gene type).
Additional file 6: Table S4. AID loci annotated with genes and listed
by chromosome coordinates. Each gene from previously annotated AID
loci using Gencode V14 (GencodeV14-protein-coding (violet), GencodeV14
all_LncRNAs (green)) and lincRNAs catalog (Cabili_LincRNAs (orange)) is
characterized by its chromosome number (Chr), the genome coordinates of
the beginning in human genome build 19 (START (hg19)) and end (END
(hg19)), the gene name (Gene ID (ENCODE/Cabili)), identification number
used in the Ensembl database (Gene ID (Ensembl)), the strand specification
(Strand), the color coded information about the gene type (Gene type) and
the listed names of AID loci in which a particular gene is located. Genes
highlighted in dark green are shared between two or more AIDs.
Additional file 7: Figure S3. Heat map visualization of overlapping
genes and loci between the autoimmune diseases studied in this paper.
(A) lncRNA genes; (B) protein-coding genes; (C) loci shared between the
pairs of diseases. CD, Crohn’s disease-specific; CeD, celiac disease;
IBD-shared, inflammatory bowel disease shared by Crohn’s disease and
ulcerative colitis; JIA, juvenile idiopathic arthritis; PBC, primary biliary
cirrhosis; PS, psoriasis; PsCh, primary sclerosing cholangitis; RA, rheumatoid
arthritis; UC, ulcerative colitis-specific. In the color scheme, red indicates the
highest number of shared properties, and white indicates the lowest
number of shared properties (see legend under each heat map).
Additional file 8: Figure S4. Circular diagram showing the disease-
specific lncRNA genes shared between nine autoimmune diseases in
detail. The nine diseases are shown on the outer circle in colored bands,
with their abbreviated names. The ribbons depicting the shared genes
are colored according to the number of disease phenotypes they are
shared by (grey, two AIDs; blue, three AIDs; red, four AIDs). The lncRNA
genes shown in this figure include genes specific to Crohn’s disease (CD),
celiac disease (CeD), inflammatory bowel disease, shared by Crohn’s
disease and ulcerative colitis (IBD_shared), juvenile idiopathic arthritis (JIA),
primary biliary cirrhosis (PBC), psoriasis (PS), primary sclerosing cholangitis
(PsCh), rheumatoid arthritis (RA), ulcerative colitis specific (UC) genes.
Additional file 9: Figure S5. Circular diagram showing the disease-
specific protein-coding genes shared between nine autoimmune diseases
in detail. The nine diseases are shown on the outer circle in colored
bands, with their abbreviated names. The ribbons depicting the shared
genes are colored according to the number of disease phenotypes they
are shared by (grey, two AIDs; blue, three AIDs; red, four AIDs; black, five
AIDs). The protein-coding genes shown in this figure include genes
specific to Crohn’s disease (CD), celiac disease (CeD), inflammatory bowel
disease, shared by Crohn’s disease and ulcerative colitis (IBD_shared),
juvenile idiopathic arthritis (JIA), primary biliary cirrhosis (PBC), psoriasis
(PS), primary sclerosing cholangitis (PsCh), rheumatoid arthritis (RA),
ulcerative colitis specific (UC) genes.
Additional file 10: Table S5. List of protein-coding genes shared
between diseases. For each disease a list of shared protein-coding genes is
provided, as well as information of which disease the gene is shared with.
CD, Crohn’s disease-specific; CeD, celiac disease; IBD-shared, inflammatory
bowel disease shared by Crohn’s disease and ulcerative colitis; JIA, juvenile
idiopathic arthritis; PBC, primary biliary cirrhosis; PS, psoriasis; PsCh, primary
sclerosing cholangitis; RA, rheumatoid arthritis; UC, ulcerative colitis-specific.
Additional file 11: Table S6. List of lncRNA genes shared between
diseases. For each disease a list of shared lncRNAs (including information
about the Gencode sub-classification) is provided, as well as information
of which disease the gene is shared with. CD, Crohn’s disease-specific;CeD, celiac disease; IBD-shared, inflammatory bowel disease shared by
Crohn’s disease and ulcerative colitis; JIA, juvenile idiopathic arthritis; PBC,
primary biliary cirrhosis; PS, psoriasis; PsCh, primary sclerosing cholangitis;
RA, rheumatoid arthritis; UC, ulcerative colitis-specific.
Additional file 12: Table S7. List of lncRNA genes shared by two or
more AIDs. All AID-shared lncRNAs (LncRNA ID_GencodeV14, n = 61) are
characterized by an identification number used in the Ensembl database
(Gene_ID_Ensembl), chromosome number (Chr), genome coordinates of
the beginning in human genome build 19 (Start (hg19)) and end (End
(hg19)), the strand specification (Strand) and the list of names of AIDs
(CD, Crohn’s disease-specific; CeD, celiac disease; IBD-shared, inflammatory
bowel disease shared by Crohn’s disease and ulcerative colitis; JIA, juvenile
idiopathic arthritis; PBC, primary biliary cirrhosis; PS, psoriasis; PsCh, primary
sclerosing cholangitis; RA, rheumatoid arthritis; UC, ulcerative colitis-specific)
in which a particular gene is located.
Additional file 13: Table S8. List of protein-coding genes shared by
two or more AIDs. All AID shared protein-coding genes (Prot-coding
ID_GencodeV14, n = 186) are characterized by identification number
used in the Ensembl database (Gene ID (Ensembl)), the chromosome
number (Chr), the genome coordinates of the beginning in human
genome build 19 (START (hg19)) and end (END (hg19)), the strand
specification (Strand) and the list of names of AIDs (CD, Crohn’s disease-
specific; CeD, celiac disease; IBD-shared, inflammatory bowel disease
shared by Crohn’s disease and ulcerative colitis; JIA, juvenile idiopathic
arthritis; PBC, primary biliary cirrhosis; PS, psoriasis; PsCh, primary
sclerosing cholangitis; RA, rheumatoid arthritis; UC, ulcerative colitis-
specific) in which a particular gene is located.
Additional file 14: Figure S6. Cell type-specific expression enrichment
of genes located in disease loci. For each disease, we compared the
proportion of expressed genes (>2 RPKM) in the whole genome (Gencode
version 14) with the proportion of expressed genes located within disease-
specific loci, similar to what we had done for all the AID loci together
(Figure 2), and tested for differences using two-tailed Fisher’s exact test.
Statistically significant enrichment (P-values after Bonferroni correction for
multiple testing) is denoted by color and plus symbols to show the different
levels of significance as defined in the legend. (A-D) Expression enrichment for
lncRNAs (top) and protein-coding genes (bottom) in seven peripheral
leukocyte (A,C) and four cord blood T-helper (B,D) cell types were calculated
for all AID loci together (all AID) as well as separately for each disease (CD,
Crohn’s disease-specific; CeD, celiac disease; IBD-shared, inflammatory bowel
disease shared by Crohn’s disease and ulcerative colitis; JIA, juvenile idiopathic
arthritis; PBC, primary biliary cirrhosis; PS, psoriasis; PsCh, primary sclerosing
cholangitis; RA, rheumatoid arthritis; UC, ulcerative colitis-specific).
Additional file 15: Figure S7. Proportion of lncRNA genes expressed in
seven peripheral blood leukocyte populations and four cord blood
T-helper cell populations, per disease. For each disease, we compared the
proportion of expressed lncRNAs (>2 RPKM) in the whole genome
(genome-wide, gray) with the proportion of expressed disease-specific
lncRNAs (red), and tested for differences using two-tailed Fisher’s exact
test. Statistically significant enrichments (P-values) after Bonferroni correction
for multiple testing are denoted by asterisks to show the different levels of
significance (*α < 0.05; **α < 0.01; ***α < 0.005). (A) Crohn’s disease-specific;
(B) celiac disease; (C) inflammatory bowel disease shared by Crohn’s disease
and ulcerative colitis; (D) juvenile idiopathic arthritis; (E) primary biliary
cirrhosis; (F) psoriasis; (G) primary sclerosing cholangitis; (H) rheumatoid
arthritis; (I) ulcerative colitis-specific.
Additional file 16: Figure S8. Proportion of protein-coding genes
expressed in seven peripheral blood leukocyte and four cord blood
T-helper cell populations, per disease. For each disease, we compared the
proportion of expressed coding genes (>2 RPKM) in the whole genome
(genome-wide, gray) with the proportion of expressed disease-specific
coding genes (red), and tested for differences using two-tailed Fisher’s
exact test. Statistically significant enrichments (P-values) after Bonferroni
correction for multiple testing are denoted by asterisks to show the
different levels of significance (*α < 0.05; **α < 0.01; ***α < 0.005).
(A) Crohn’s disease-specific; (B) celiac disease; (C) inflammatory bowel disease
shared by Crohn’s disease and ulcerative colitis; (D) juvenile idiopathic
arthritis; (E) primary biliary cirrhosis; (F) psoriasis; (G) primary sclerosing
cholangitis; (H) rheumatoid arthritis; (I) ulcerative colitis-specific.
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expression in seven peripheral blood leukocyte and four cord blood
T-helper cell populations. Each panel is shown as a separate file with a
higher resolution so that the gene IDs can be read easily. (A-D) The heat
maps show expression of all genes located in AID loci ((A) lncRNAs, (B)
protein-coding genes) and AID genes shared by at least two diseases ((C)
lncRNAs, (D) protein-coding genes) in all 11 cell types (granulocytes,
monocytes, NK cells, B cells, memory T cells (both CD4+ and CD8+), naive
CD4+and naive CD8+ T cells (cytotoxic T cells), precursor T-helper cells
(ThP), primary T-helper cells (Th0) and polarized T cells (Th1, Th2)). In the
color scheme, saturated red indicates three-fold up-regulation, saturated
green indicates three-fold down-regulation, and black indicates unchanged
expression. (A) RNA sequencing analysis of gene expression in seven
peripheral blood leukocyte and four cord blood T-helper cell populations -
240 AID lncRNAs. (B) RNA sequencing analysis of gene expression in seven
peripheral blood leukocyte and four cord blood T-helper cell populations -
626 AID protein-coding genes. (C) RNA sequencing analysis of gene
expression in seven peripheral blood leukocyte and four cord blood
T-helper cell populations - 61 lncRNAs shared between at least two AIDs.
(D) RNA sequencing analysis of gene expression in seven peripheral blood
leukocyte and four cord blood T-helper cell populations - 186 protein-
coding genes shared between at least two AIDs.
Additional file 18: Table S9. Results from pathway analysis using the
GeneNetwork tool of nine AID shared lncRNAs. Nine out of 61 AID shared
lncRNAs were present in the GeneNetwork database. Each lncRNA gene
(LncRNA ID_GencodeV14) is characterized by an identification number used
in the Ensembl database (Gene_ID_Ensembl), its chromosome number
(Chr), the genome coordinates of the beginning in human genome build
19 (START (hg19)) and end (END (hg19)), the strand specification (Strand)
and the list of names of AIDs (CD, Crohn’s disease-specific; CeD, celiac
disease; IBD-shared, inflammatory bowel disease shared by Crohn’s disease
and ulcerative colitis; JIA, juvenile idiopathic arthritis; PBC, primary biliary
cirrhosis; PS, psoriasis; PsCh, primary sclerosing cholangitis; RA, rheumatoid
arthritis; UC, ulcerative colitis-specific) in which a particular gene is located.
We extracted the information about the function prediction from GeneNet-
work [57] and listed the top 10 most significant Gene Ontology terms (GO)
for biological process and another top 10 most significant GO terms for
molecular function together with the P-value. GO terms containing ‘tumor
necrosis factor (TNF) pathway’ or ‘T-cell/lymphocyte event’ in their
description are highlighted in yellow.
Additional file 19: Figure S10. Region IL21/IL21-AS1 as an example of
a locus with a prioritized cell type. (A) Genomic overview of the region
including four protein-coding genes (KIAA1109, ADAD1, IL2, IL21) and
one lncRNA gene (IL21-AS1). (B) Expression of genes located in this
region. T-helper 1 (Th1) cells are prioritized based on the co-expression
levels of IL21 and IL21-AS1 (red ellipse).Abbreviations
AID: autoimmune and immune-related disorder; CD: Crohn’s disease; CeD: celiac
disease; ENCODE: Encyclopedia of DNA Elements; eQTL: expression quantitative
trait locus; GO: Gene Ontology; GWAS: genome-wide association studies;
HLA: human leukocyte antigen; IBD: inflammatory bowel disease; IL: interleukin;
JIA: juvenile idiopathic arthritis; lncRNA: long non-coding RNA; NK: natural killer;
PBC: primary biliary cirrhosis; PBMC: peripheral blood mononuclear cell;
PS: psoriasis; PsCh: primary sclerosing cholangitis; RA: rheumatoid arthritis;
RPKM: reads per kilobase per million mapped reads; SNP: single-nucleotide
polymorphism; Th: T-helper; Th0: primary T-helper; ThP: precursor T-helper;
UC: ulcerative colitis.
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